Vascular Graft Market by Raw Material (Biological Materials, Polyester, Polytetrafluoroethylene), Product (Coronary Artery By-Pass Graft, Endovascular Stent Graft, Hemodialysis Access Graft), Application, End-User - Global Forecast 2024-2030

Vascular Graft Market by Raw Material (Biological Materials, Polyester, Polytetrafluoroethylene), Product (Coronary Artery By-Pass Graft, Endovascular Stent Graft, Hemodialysis Access Graft), Application, End-User - Global Forecast 2024-2030

The Vascular Graft Market size was estimated at USD 3.51 billion in 2023 and expected to reach USD 3.77 billion in 2024, at a CAGR 7.39% to reach USD 5.79 billion by 2030.

A vascular graft is a surgical process that redirects blood flow around a blocked or partially blocked artery in the heart by using a blood vessel taken from another part of your body, also known as a graft. Vascular grafts can be made from various materials, including synthetic polymers, such as polytetrafluoroethylene (PTFE) and polyurethane, and biological materials, such as collagen and human or animal tissue. The rise in the prevalence of vascular disorders and the rise in the geriatric population prone to cardiovascular diseases increases the adoption of vascular grafts. However, the risk of complications post-implantation of a vascular graft, such as graft infection and blood clots, may further hinder the adoption of the vascular graft. Nevertheless, the rise of biomaterial research for developing advanced, biocompatible grafts and the ongoing advancements in vascular imaging technologies such as 3D angiography offer potential for significant growth opportunities for the market.

Regional Insights

The vascular graft market is evolving in the Americas owing to technological advancements, rising healthcare expenditure, and the prevalence of cardiovascular disorders and diabetes in the region. Strong focus on regulatory compliance and safety measures, substantial research and development projects, increasing awareness regarding vascular grafts, and growing healthcare infrastructure encourage using vascular graft procedures to improve treatment outcomes in the EMEA region. Growing prevalence of lifestyle diseases and the accelerating expansion of healthcare services, significant medical technology advancements are resulting in the development of enhanced vascular graft procedures in the APAC region. Besides, the development of bioengineered vascular grafts that mimic the natural blood vessel structure and composition is anticipated to increase the use of this medical procedure by health professionals to treat various medical conditions.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Vascular Graft Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing prevalence of lifestyle-related disorders globally
• Growing preference for minimally invasive procedures
• Rising number of clinical trials of vascular grafts

Market Restraints

• High treatment cost of vascular graft procedures

Market Opportunities

• Improvements in the design and performance of vascular grafts
• Development of tissue-engineered vascular grafts

Market Challenges

• Infections associated with vascular grafts

Market Segmentation Analysis

• Raw Material: Burgeoning utilization of polytetrafluoroethylene-based vascular grafts owing to their biocompatibility and flexibility
• Product: Proliferating usage of peripheral vascular graft for restoring blood flow in patients with blockages in the peripheral arteries
• Application: Significant use of vascular grafts in treating cardiovascular diseases
• End-User: Significant applications of vascular grafts in ambulatory surgical centers (ASCs)

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Vascular Graft Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Vascular Graft Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Aquedeon Medical, Inc. Receives FDA IDE Approval for the Duett Vascular Graft System

Aquedeon Medical, Inc. has received FDA Investigational Device Exemption (IDE) approval to conduct a staged pivotal clinical trial for its Duett Vascular Graft System in the United States. The Duett Vascular Graft System is designed with the aim of standardizing and simplifying open surgical thoracic aortic procedures. It achieves this by connecting native aortic arch branch vessels to the surgical graft without the need for suturing each anastomosis. This innovative approach has the potential to decrease deep hypothermic circulatory arrest (DHCA) and overall procedure time, thus reducing the risk of severe complications.

Xeltis’ aXess Vascular Graft Development Receives Funding From European Innovation Council

Vascular Graft Xeltis, a Netherlands-based developer of cardiovascular living implants, received Euro 12.5 million in funding from the European Innovation Council (EIC) Fund to support vital clinical trials of its vascular graft product, aXess. These trials include a first-in-human (FIH) trial for patients with Chronic Kidney Disease requiring hemodialysis, as well as a pivotal trial enrolling patients across Europe.

Vygon Partners with Carmat to Develop a Vascular Graft for an Artificial Heart

Vygon has partnered with Carmat to develop two prosthetic outflow tracts for their Aeson artificial heart device. By the fourth quarter of 2024, Vygon plans to utilize its existing vascular graft and create a second bespoke device. The Aeson device is currently available in the European Union and is undergoing evaluation in the United States through an early feasibility study.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Vascular Graft Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Vascular Graft Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Affluent Medical, B. Braun Melsungen AG, Becton, Dickinson and Company, BIOVIC Sdn. Bhd., Boston Scientific Corporation, Cardinal Health Inc., Cook Medical, Inc., Corcym S.r.l., CryoLife, Inc., Endologix Inc., Getinge AB, Heart Medical Europe B.V., Japan Lifeline Co., Ltd., Lemaitre Vascular, Inc., Medtronic PLC, Merit Medical Systems, Inc., Perouse Medical SAS by Vygon SAS, Rua Life Sciences PLC, Shanghai Suokang Medical Implants Co. Ltd., Terumo Corporation, Vascular Graft Solutions Ltd., VUP Medical, W. L. Gore & Associates, Inc., and Xeltis B.V..

Market Segmentation & Coverage

This research report categorizes the Vascular Graft Market to forecast the revenues and analyze trends in each of the following sub-markets:

Raw Material

Biological Materials

Human Saphenous & Umbilical Veins

Tissue Engineered Materials

Polyester

Polytetrafluoroethylene

Polyurethane

Product

Coronary Artery By-Pass Graft

Endovascular Stent Graft

Hemodialysis Access Graft

Peripheral Vascular Graft

Application

• Aneurysm
• Cardiovascular
• Diabetes
• Kidney Failure
• Vascular Occlusion
• End-User
• Ambulatory Surgical Center
• Hospital

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year